With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
MDT trades against a final fair-value range of $78.26-$113.75, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A prolonged period of sluggish top-line growth combined with intense pricing pressure and hospital capital constraints severely compresses operating margins below the 19.5% baseline, threatening Medtronic's reliable free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics. and forcing a cut to its high dividend payout.
Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
Macroeconomic pressures force severe hospital capital constraints and widespread deferral of elective procedures, crushing revenue growth to negative territory.
Pricing pressure and margin erosion reduce free cash flow such that the 79% dividend payout becomes unsustainable, triggering massive multiple compression.
| Line item | 2022-04-30 | 2023-04-30 | 2024-04-30 | 2025-04-30 | Trend |
|---|---|---|---|---|---|
| Revenue | $31.69B | $31.23B-1.5% | $32.36B+3.6% | $33.54B+3.6% | +1.9% |
| Gross profit | $21.54B | $20.51B | $21.15B | $21.91B | +0.6% |
| Operating income | $5.91B | $5.83B | $5.52B | $6.54B | +3.4% |
| Net income | $5.04B | $3.76B-25.4% | $3.68B-2.1% | $4.66B+26.6% | -2.6% |
| EPS (diluted) | $3.73 | $2.82 | $2.76 | $3.61 | -1.1% |
| EBITDA | $8.78B | $8.70B | $8.20B | $9.22B | +1.6% |
| R&D | $2.75B | $2.70B | $2.74B | $2.73B | -0.2% |
| SG&A | $10.29B | $10.42B | $10.74B | $10.85B | +1.8% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Dividend payout ratio exceeds 90% of sustainable free cash flow. | Monitor | Deterioration versus the report thesis |
| Major clinical trial failures or FDA rejections in key growth segments. | Monitor | Deterioration versus the report thesis |
